Since its inception, PBI has carefully built a functional structure based on expert consultants and has employed only essential personnel and used service contractors for operations to preserve its limited resources. The organization chart shown below indicates the structure we continue to build on, followed by descriptions of key positions/structures that are currently filled.
CHAIRMAN
Lily Wu, Ph.D. , Chairman & CEO
Lily Wu is the Chairman of PBI and holds a PhD in Business Administration from Feng Chia University. With decades of corporate leadership experience, she has worked in business development, marketing, and management at Universal Unity Development Corporation.
Drew Hannaman, Vice President
Drew Hannaman has over 25 years of experience in the development and clinical translation of novel biopharmaceutical and medical device product candidates with a specialization in nucleic acid based biologics and associated delivery technologies. He is a co-inventor of the electroporation based TriGrid Delivery System under development at Papivax Biotech and is a co-author of over 50 publications describing the use of the electroporation mediated delivery of nucleic acid based biologics. He holds a degree in Cybernetics from the University of California, Los Angeles.
Yung-Nien Chang, Ph.D. , Chief Scientific Officer
Dr. Chang has almost 30 years of drug development experience within the US biopharma industry; including Genetic Therapy, Inc./Novartis, VIRxSYS Corp, Lentigen Corp, and Synaptic Research, LLC. He has operational experience with clinical stage assets and prior experience as CSO.
Connie Lai , Finance Manager
Connie Lai started Finance career from 1992 in a global company for 30 years and has held various finance positions with increasing responsibility, in 2010, Connie took on a Region assignment in China to oversee all aspects of 6 countries’ finance activities from AR, AP, payroll, billing, collection, internal audit, month end closing to annual business plan. In this role Connie made significant achievement in growing productivity and process improvement to meet company and customer’s demand.
Kent Yeh, Ph.D. , Director of Product Development
Kent Yeh obtained his Ph.D. in Biochemistry and Molecular Biology from Yang Ming University. He has a rich and extensive background in nucleic acid research and CMC management, having previously worked at Oneness Biotech and Avirovac Biotech. Kent has led teams in the development of nucleic acid molecules and protein vaccines and successfully advanced them to the production manufacturing stage. Currently, he holds the position of Director of Research and Development at Papivax Biotech, where he is responsible for managing the R&D team and overseeing CMC-related matters.
Barry Ellefsen, Medical Device Manager
Barry Ellefsen has over 20 years of experience in the development and clinical translation of novel medical device product candidates and is a co-developer of the electroporation based TriGrid Delivery System. He has co-authored 12 publications describing the use of the electroporation mediated delivery of nucleic acid-based biologics. Barry is a graduate of the University of California – San Diego with a B.S. degree in Physiology and Neuroscience.
Roy Tseng, Project Manager
Roy Tseng graduated from the Taipei Medical University with master of Public Health. Previously, he worked for Novotech as a clinical project manager. He has great expertise and experience in accounting, data analysis, clinical trial conduction and project management.
Legal services
Legal services contracted with WISPRO Law Offices of International Commerce, Taipei, Taiwan